Opens in a new tab

Europe’s Preventable RSV Winter

New ECDC modelling suggests that protecting newborns against RSV could prevent a substantial share of infant hospitalisations during the first months of life. Under a scenario reaching 90% of newborns with long-acting monoclonal antibodies, 61% of RSV hospitalisations in the first two months could be prevented. Europe has the preventive tools. The challenge is making…

November 12, 2026
Editorial
RSV prevention during early infancy depends on timely maternal or newborn immunisation, reliable access to preventive products and coordinated delivery through maternity and paediatric services.SeventyFour / Shutterstock.com

IPM Take

Europe cannot keep treating predictable infant hospitalisations as an unavoidable winter pressure when preventive options already exist.

ECDC’s modelling provides a compelling argument for integrating RSV prevention into maternal and newborn care. But a national recommendation does not protect an infant if eligibility rules are restrictive, reimbursement is delayed or maternity services are not equipped to deliver protection before exposure. The next policy debate should be about how countries turn promising preventive evidence into equitable population coverage.

Executive Summary

ECDC published a multi-model assessment on 28 October examining the potential impact of newborn RSV immunisation across the EU/EEA.

Under a modelled scenario in which 90% of newborns receive long-acting monoclonal antibodies at birth, the analysis projects that approximately 61% of RSV-related hospitalisations during the first two months of life could be prevented. Universal maternal vaccination was estimated to prevent approximately 52% of hospitalisations in the same early-life period.

These figures are modelled projections under specified assumptions, not observed reductions from a single European programme. They provide evidence to inform national decisions on preventive strategy, delivery pathways and coverage.

Why it matters

  • Payers and health ministries: Need to evaluate the costs of prevention against avoidable hospitalisation and seasonal pressure on paediatric services.
  • Maternity and paediatric providers: Must coordinate eligibility, product administration, documentation and follow-up before newborns encounter their first RSV season.
  • Families: Access should not depend on where a child is born, whether parents understand an unfamiliar preventive product or whether hospitals operate different local policies.

Cancer care is no longer organised only around tumour site and stage. It is increasingly organised around the biological information that tells clinicians what the tumour is doing and which options may be available.

That makes sequencing infrastructure a quiet but decisive access issue. A RAS inhibitor, an ADC strategy, a ctDNA-guided switch or a trial match may all depend on whether genomic information exists in time. If the result arrives after treatment has already started, the system has already lost part of the value.

The policy question is therefore practical: who gets sequenced, when, where and at whose cost? Comprehensive genomic solutions can support earlier and better decisions, but only if they are connected to referral rules, reimbursement, laboratory capacity and clinical interpretation.

For IPM, the message is simple. The precision oncology race is not only about drugs. It is about whether health systems can build the genomic operating system that makes those drugs usable.

Source & Evidence